Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant anti-VEGF humanized monoclonal antibody
- Development stage
- Phase 3
- Lead developer
- EddingGenor Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intravitreal
01
Overview
Recombinant anti-VEGF humanized monoclonal antibody is a generic term used in clinical trial registries (particularly in China) to describe biosimilars of bevacizumab. Bevacizumab is a recombinant humanized IgG1 monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A). By binding to VEGF-A, it prevents the interaction of VEGF with its receptors (Flt-1/VEGFR1 and KDR/VEGFR2) on the surface of endothelial cells, thereby inhibiting angiogenesis, endothelial cell proliferation, and tumor vascularization. This class of biosimilars is being developed by various pharmaceutical companies for indications including non-small cell lung cancer (NSCLC), colorectal cancer, glioblastoma, diabetic macular edema (DME), and wet age-related macular degeneration (wAMD).
- Other names
- recombinant anti-VEGF humanized monoclonal antibody injectionrecombinant humanized anti-VEGF monoclonal antibody重组抗VEGF人源化单克隆抗体
02
Targets
VEGFA (Vascular endothelial growth factor A)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on recombinant anti-VEGF humanized monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant anti-VEGF humanized monoclonal antibody.